Table 2.
Trimetazidine | Placebo | |
LA (mm) | 52.6 ± 2.1 | 51.9 ± 1.7 |
LVEDD (mm) | 63.2 ± 2.1 | 62.4 ± 1.7 |
LVESD (mm) | 41.1 ± 1.5 | 39.5 ± 1.3 |
LVEF (%) | 32.3 ± 5.3 | 32.8 ± 2.3 |
LV Wall Motion Index Score | 1.37 ± 0.2 | 1.38 ± 0.3 |
E/A | 0.68 ± 0.1 | 0.64 ± 0.12 |
Baseline echocardiographic parameters in patients randomized to trimetazidine or placebo. No significant differences in echocardiographic and Doppler measures were found between the two groups at baseline.